Partnerships
Our allies in realizing the potential of neurogenetic medicine
Voyager has entered into a number of different business development arrangements for our TRACER-derived capsids and for our programs. Examples include:
Capsid Licenses
PROVIDE:
- Validation (third-party buy-in, potential program use)
- Near-term funding (upfront and option exercise payments)
- Long-term funding
(milestones and royalties) - Multiple ‘shots on goal’ to prove human translation
Program Partnerships
PROVIDE:
- Significant long-term potential value (profit share or milestones and royalties)
- Cost savings (program funding)
- Validation (investment into program)
- Near-term funding (upfront, early development milestone payments)
Additional Structures
PROVIDE:
- Opportunities to combine TRACER capsids and receptor technology with cutting-edge payloads and biologics, placing Voyager at forefront of neurogenetic medicine
- Various deal structures with range of participation being explored